Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003873 (rheumatoid arthritis)
 53,068 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Benoxaprofen is a new nonsteroidal analgesic anti-inflammatory drug with a long half-life. Preliminary studies showed that steady-state blood levels could be achieved within 24 hours of treatment using a dose of 300 mg on the first day followed by 100 mg twice daily. A double-blind cross-over trial showed that benoxaprofen was effective and well tolerated in rheumatoid arthritis. Its analgesic effect was not apparent until the sixth day of treatment. An unusual trial design was used with treatment periods of unequal duration. This design has the advantage of allowing a new drug to be given for long enough to determine the time course of its action, while sparing patients prolonged treatment with placebo.
 ...
PMID:Benoxaprofen: a clinical trial with an unusual design. 36 21

By initial 3H-thymidine labelling an enhanced monocyte proliferation in the bone marrow of patients with rheumatoid arthritis is demonstrated. The significant monocyte proliferation correlates positively with the erythrocyte sedimentation rate but shows a negative correlation with age. The high significance of the mononuclear phagocyte (MNP) system in the pathogenesis of rheumatoid arthritis is seriously underlined by the experimental findings in our allergic arthritis model. Benoxaprofen as an inhibitor of the lipoxygenase pathway and of the inflammatory monocyte influx significantly suppresses the experimental allergic synovitis. These findings stress upon the important role of the MNP-system in the pathogenesis of rheumatoid arthritis and demonstrate the significance of the monocytes/macrophages as an important target-cell system for antirheumatic drugs.
 ...
PMID:[Pathogenesis and therapy of rheumatoid inflammation]. 348 11

Benoxaprofen is a nonsteroidal anti-inflammatory agent that belongs to the arylalkanoic acid class of antirheumatic drugs. Animal studies have demonstrated that it has analgesic, antipyretic, and anti-inflammatory properties. Although benoxaprofen is a relatively weak inhibitor of cyclo-oxygenase in in vitro systems, inhibits lipoxygenase in other systems, and inhibits monocyte migration in some animal models of inflammation, it has not been established that it is unique with regard to these actions. Benoxaprofen undergoes hepatic metabolism via glucuronidation as the primary route of elimination and has a half-life of 28-35 hr. Clinical trials have demonstrated that its analgesic and anti-inflammatory properties are useful in the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Once daily dosing of 300-600 mg is effective for many patients. In addition to gastrointestinal intolerance, photosensitivity and onycholysis are the most frequent adverse effects encountered. Recent reports of fatal cholestatic jaundice often associated with nephrotoxicity led to the withdrawal of benoxaprofen from world markets. It is uncertain whether it will once again be available for clinical use.
 ...
PMID:Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen. 676 31

This multicenter double-blind clinical trial compared the efficacy and safety of benoxaprofen and naproxen in the treatment of rheumatoid arthritis. The studies followed a crossover design which provided 6 wk therapy with each of the 2 study drugs. Benoxaprofen at a single daily dose of 600 mg compared favorably to naproxen, 750 mg, administered in 2 equally divided doses. All efficacy results indicated slightly more improvement with benoxaprofen although the difference between the 2 drugs was not significant. Side effects were generally mild and only 1 patient discontinued benoxaprofen therapy because of a reactivation of a duodenal ulcer.
 ...
PMID:Crossover comparison of benoxaprofen and naproxen in rheumatoid arthritis. 699 66

The new nonsteroidal antiinflammatory drug benoxaprofen was compared with placebo in separate double-blind crossover studies in patients with active rheumatoid arthritis given 400 mg, 600 mg, or 800 mg a day. Benoxaprofen was significantly better than placebo at all doses studied. The 800 mg dose was the most effective but there were slightly more gastrointestinal side effects with this dose. The 600 mg dose was more effective than the 400 mg dose with an acceptably low incidence of side effects at both these doses. For most patients, 600 mg once daily will probably be the usual dose of the drug, but some will need the higher dose to 800 mg, while the condition of others may be satisfactorily controlled with just 400 mg daily.
 ...
PMID:Dose-range studies of benoxaprofen compared with placebo in patients with active rheumatoid arthritis. 699 73

Benoxaprofen is a nonsteroidal anti-inflammatory agent with a novel spectrum of pharmacological activity including regulatory effects on monocytes. It significantly reduces the serum alkaline phosphatase in patients with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The reduction usually has been within the normal range, but sometimes there has been a change from an abnormal to a normal value. The possible significance of this observation and ways of examining it further are discussed in this review. The reduction may be an effect on osteoblasts secondary to an effect on osteoclasts, cells known to be derived from monocyte precursors. If so, benoxaprofen should be effective in Paget's disease of the bone and preliminary data suggest this may be so.
 ...
PMID:Benoxaprofen and its effect on serum alkaline phosphatase: a review. 704 96

The safety and efficacy of benoxaprofen (300 or 600 mg) and indomethacin 75 to 150 mg) were compared in optimum dosage levels for 91 patients with rheumatoid arthritis or osteoarthritis. These multicenter studies were conducted by eight investigators. Overall, the two drugs brought significant and similar improvements in both indications. Benoxaprofen responses were significantly better for several rheumatoid arthritis efficacy measurements, while indomethacin exhibited better responses in some osteoarthritis parameters. Adverse effects were similar for both drugs but fewer drug-related side effects were observed with benoxaprofen. Mild to moderate gastrointestinal complaints were reported with both drugs. In the rheumatoid arthritis study, onycholysis appeared in three patients taking indomethacin although two had received benoxaprofen as first therapy. Unfavorable trends in some laboratory values occurred in nearly twice as many patients on indomethacin. These results were obtained with once-daily benoxaprofen dosage compared to three-times-daily administration of indomethacin at total daily doses titrated to the individual patients.
 ...
PMID:Crossover comparison of benoxaprofen and indomethacin in rheumatoid arthritis and osteoarthritis. 704